Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer

Documenti analoghi

• Regorafenib versus Cetuximab plus Irinotecan in Third-line Metastatic Colorectal Cancer in Iran: A Model-based Cost-utility Analysis
  di: Meysam Seyedifar, et al.
  Pubblicazione: (2024-10-01)
• EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
  di: Frifeldt Sanne K, et al.
  Pubblicazione: (2011-03-01)
• Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
  di: Maria Ignez Freitas Melro Braghiroli, et al.
  Pubblicazione: (2024-01-01)
• Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
  di: Adams, R, et al.
  Pubblicazione: (2008)
• First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
  di: Yu‐Wen Zhou, et al.
  Pubblicazione: (2021-05-01)